Prevention of stroke in patients with atrial fibrillation: The role of new antiarrhythmic and antithrombotic drugs

Cerebrovascular Diseases

Volumn 30, Issue 3, 2010, Pages 314-322

  Röther, Joachim ^a,b   Crijns, Harry ^c  

^a KLINIKUM MINDEN   (Germany)

^b ASKLEPIOS KLINIK ALTONA   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiarrhythmic drug; Anticoagulation; Atrial fibrillation; Ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DABIGATRAN; DRONEDARONE; IRBESARTAN; PLACEBO; SOTALOL; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART RATE AND RHYTHM; HUMAN; LIVER FUNCTION TEST; MORBIDITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; FIBRINOLYTIC AGENTS; HUMANS; PYRIDINES; RISK FACTORS; STROKE;

EID: 77954884671     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319608     Document Type: Review

References (69)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S: ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE: The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
4. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS: Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 2007; 49: 986-992.
5. Stewart S, Hart CL, Hole DJ, McMurray JJ: A population-based study of the long-term risks associated with atrial fibrillation: 20- year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
6. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
7. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-1056.
8. Boysen G, Nyboe J, Appleyard M, Sorensen PS, Boas J, Somnier F, Jensen G, Schnohr P: Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 1988; 19: 1345-1353.
9. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB: Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889-894.
10. Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, Paik MC, Shea S: Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke 2001; 32: 1725-1731.
11. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GY, Crijns HJ: Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008; 29: 915-922.
12. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, Favale S, Zolezzi F, Di Belardino N, Molon G, Drago F, Villani GQ, Mazzini E, Vimercati M, Grammatico A: Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1920.
13. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation: The Framingham Study. Stroke 1996; 27: 1760-1764.
14. Lavy S, Stern S, Melamed E, Cooper G, Keren A, Levy P: Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 1980; 11: 35-38.
15. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A: Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population- based study. Stroke 2005; 36: 1115-1119.
16. Dhamoon MS, Tai W, Boden-Albala B, Rundek T, Paik MC, Sacco RL, Elkind MS: Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke 2007; 38: 1752-1758.
17. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS: Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66: 641-646.
18. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, John CA, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G: Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference research perspectives in AF. Eur Heart J 2009; 30: 2969-2977.
19. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R: Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647-1651.
20. Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, Jarouse J, Brillman J, Murali S, Gupta R: Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008; 71: 1696-1701.
21. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH: Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47-52.
22. Savelieva I, Camm AJ: Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4: 369-382.
23. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
24. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
25. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
26. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL: Primary prevention of ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 1583-1633.
27. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617.
28. National Institute for Health and Clinical Excellence: Stroke: diagnosis and initial management of acute stroke and transient ischemic attack (TIA). NICE Clinical Guideline 68. National Guideline Clearinghouse Website. http://guideline.gov/summary/ summary.aspx?ss=15&doc-id=14328& string= (accessed April 20, 2010).
29. Paciaroni M, Agnelli G, Micheli S, Caso V: Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a metaanalysis of randomized controlled trials. Stroke 2007; 38: 423-430.
30. Adams HP Jr: Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002; 33: 856-861.
31. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
32. O'Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, Guyatt G, Gould L, D'Uva C, Kapral M, Silver F: Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 2006; 5: 749-754.
33. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
34. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS: A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007; 36: 151-156.
35. Hughes M, Lip GY: Risk factors for anticoagulation- related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007; 100: 599-607.
36. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.
37. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
38. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
39. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P: Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-486.
40. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
41. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U: Randomized trial of rate-control versus rhythmcontrol in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
42. Sherman DG: Stroke prevention in atrial fibrillation: pharmacological rate versus rhythm control. Stroke 2007; 38(suppl 2): 615-617.
43. Camm AJ, Reiffel JA: Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl 2008; 10(suppl H):H55-H78.
44. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD: Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-1872.
45. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ: Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
46. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH: Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallelarm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120: 1174-1180.
47. Ezekowitz MD, Koti MJ, Fulton B: Reducing stroke rates in patients with atrial fibrillation: how low can we go? Circulation 2009; 120: 1169-1170.
48. Trujillo TC, Nolan PE: Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 2000; 23: 509-532.
49. Multaq Prescribing Information. Bridgewater, Sanofi-Aventis US LLC, 2009.
50. National Institute for Health and Clinical Excellence: Atrial fibrillation - dronedarone: appraisal consultation document 2. NICE Website. http://www.nice.org.uk/ guidance/index.jsp?action=article&o=48099 (accessed April 20, 2010).
51. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
52. Morley J, Marinchak R, Rials SJ, Kowey P: Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996; 77: 38A-44A.
53. Van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE: Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410-1416.
54. Andersen KK, Olsen TS: Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a Danish quality-control registry of 22,170 patients with ischemic stroke. Stroke 2007; 38: 259-263.
55. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
56. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, Wilson PW, Corbalan R, Aichner F, Steg PG: Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-863.
57. Waldo AL, Becker RC, Tapson VF, Colgan KJ: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 2005; 46: 1729-1736.
58. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026.
59. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH, Levy S, Crijns HJ: Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation: The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007; 153: 1006-1012.
60. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for highrisk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
61. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-1912.
62. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Yusuf S: Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med 2009; 360: 2066-2078.
63. Diener HC: Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21: 279-293.
64. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
65. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698.
66. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
67. Luengo-Fernandez R, Gray AM, Rothwell PM: Costs of stroke using patient-level data: a critical review of the literature. Stroke 2009; 40:e18-e23.
68. Maddox TM, Nash IS, Fuster V: Economic costs associated with atrial fibrillation; in Natale A, Jalife J (eds): Atrial Fibrillation, Bench to Bedside. Totawa Humana Press, 2008.
69. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J, Nolte CH, Jungehulsing GJ, Villringer A, Willich SN: The impact of atrial fibrillation on the cost of stroke: the Berlin Acute Stroke study. Value Health 2007; 10: 137-143.